Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

Objective Response ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Survival Outcome ◽

Free Survival ◽

Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4

Annals of Oncology ◽

10.1093/annonc/mdx365.007 ◽

2017 ◽

Vol 28 ◽

pp. v77-v78

Author(s):

T. Bachelot ◽

M. Royce ◽

C. Villanueva ◽

F. Melo Cruz ◽

R. Hegg ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Free Survival ◽

Subgroup Analyses ◽

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2

Annals of Oncology ◽

10.1093/annonc/mdy272.322 ◽

2018 ◽

Vol 29 ◽

pp. viii107-viii108

Author(s):

H.S. Rugo ◽

R.S. Finn ◽

K.A. Gelmon ◽

A.A. Joy ◽

O.N. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Objective Response ◽

Growth Factor Receptor ◽

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽

Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-01 ◽

2020 ◽

Author(s):

Erika Hamilton ◽

Patricia LoRusso ◽

Cynthia Ma ◽

Neelima Vidula ◽

Rebecca G Bagley ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽

Receptor Modulator ◽

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer

Cancer Science ◽

10.1111/cas.12897 ◽

2016 ◽

Vol 107 (4) ◽

pp. 491-498 ◽

Cited By ~ 19

Author(s):

Mai Tomiguchi ◽

Yutaka Yamamoto ◽

Mutsuko Yamamoto‐Ibusuki ◽

Lisa Goto‐Yamaguchi ◽

Yoshitaka Fujiki ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Fibroblast Growth Factor Receptor ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Cancer ◽

10.1002/cncr.30143 ◽

2016 ◽

Vol 122 (19) ◽

pp. 3032-3040 ◽

Cited By ~ 11

Author(s):

Florence Lerebours ◽

Sofia Rivera ◽

Marie-Ange Mouret-Reynier ◽

Severine Alran ◽

Laurence Venat-Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Postmenopausal Estrogen ◽

Epidermal Growth ◽

Randomized Phase 2